Display options
Cite
Probst S, Abikhzer G, Chaussé G, et al. Diferansiye Tiroid Kanser Tedavisinde I-131 Radyasyona Bağlı Miyelosüpresyon. I-131 Radiation-Induced Myelosuppression in Differentiated Thyroid Cancer Therapy. Mol Imaging Radionucl Ther. 2018;27(2):84-87doi: 10.4274/mirt.59454.
Probst, S., Abikhzer, G., Chaussé, G., & Tamilia, M. (2018). Diferansiye Tiroid Kanser Tedavisinde I-131 Radyasyona Bağlı Miyelosüpresyon. I-131 Radiation-Induced Myelosuppression in Differentiated Thyroid Cancer Therapy. Molecular imaging and radionuclide therapy, 27(2), 84-87. https://doi.org/10.4274/mirt.59454
Probst, Stephan, et al. "Diferansiye Tiroid Kanser Tedavisinde I-131 Radyasyona Bağlı Miyelosüpresyon." I-131 Radiation-Induced Myelosuppression in Differentiated Thyroid Cancer Therapy. Molecular imaging and radionuclide therapy vol. 27,2 (2018): 84-87. doi: https://doi.org/10.4274/mirt.59454
Probst S, Abikhzer G, Chaussé G, Tamilia M. Diferansiye Tiroid Kanser Tedavisinde I-131 Radyasyona Bağlı Miyelosüpresyon. I-131 Radiation-Induced Myelosuppression in Differentiated Thyroid Cancer Therapy. Mol Imaging Radionucl Ther. 2018 Jun 07;27(2):84-87. doi: 10.4274/mirt.59454. PMID: 29889031; PMCID: PMC5996605.
Copy Download .nbib Format: NLM
Share it on

Mol Imaging Radionucl Ther. 2018 Jun 07;27(2):84-87. doi: 10.4274/mirt.59454.

I-131 Radiation-Induced Myelosuppression in Differentiated Thyroid Cancer Therapy.

Molecular imaging and radionuclide therapy

Stephan Probst, Gad Abikhzer, Guillaume Chaussé, Michael Tamilia

Affiliations

  1. Jewish General Hospital, Clinic of Nuclear Medicine, Montreal, Canada.
  2. Jewish General Hospital, Clinic of Endocrinology, Montreal, Canada.

PMID: 29889031 PMCID: PMC5996605 DOI: 10.4274/mirt.59454

Abstract

Radioactive iodine (RAI) treatment of differentiated thyroid cancer has been used in clinical practice for almost 60 years and is generally accepted to be a safe and efficacious treatment. Severe toxicity in the form of radiation pneumonitis, sometimes progressing to fibrosis, and bone marrow suppression are reported but remain rare. We present a case of severe myelosuppression requiring hospitalization and transfusion support in an otherwise well, young female patient who had received 175 mCi I-131 for low-volume micronodular lung disease one month prior, with a cumulative lifetime administered activity of 575 mCi. The most important risk factors for myelosuppression following RAI are the activity received, the amount of functioning thyroid tissue present, and the lifetime cumulative activity received.

Keywords: Iodine radioisotopes; bone marrow thyroid neoplasms.

References

  1. Nuklearmedizin. 2007;46(4):121-8 - PubMed
  2. Nucl Med Commun. 2007 Mar;28(3):215-23 - PubMed
  3. J Nucl Med. 1996 Apr;37(4):633-6 - PubMed
  4. J Nucl Med. 2004 Sep;45(9):1549-54 - PubMed
  5. J Nucl Med. 2006 Oct;47(10):1587-91 - PubMed
  6. Acta Oncol. 1990;29(8):1035-9 - PubMed
  7. J Nucl Med. 1996 Sep;37(9):1496-503 - PubMed
  8. J Nucl Med. 2003 Mar;44(3):451-6 - PubMed
  9. J Natl Compr Canc Netw. 2007 Jul;5(6):631-40 - PubMed
  10. Chin Med J (Engl). 1995 Oct;108(10):796-7 - PubMed

Publication Types